XML 36 R3.htm IDEA: XBRL DOCUMENT v3.20.1
CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS - CAD ($)
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Income Statement [abstract]    
Revenue $ 257,099  
Cost of revenue 1,959,111  
Gross loss before fair value adjustments (1,702,012)  
Fair value adjustments on inventory sold 22,249  
Unrealized loss on changes in fair value of biological assets 682,739  
Gross loss (2,407,000)  
Expenses    
General and administrative 14,811,529 $ 18,740,360
Share-based payments 16,061,319 6,440,406
Depreciation and amortization 3,146,680 183,194
Allowance for impairment of Auxly funds   7,499,977
Impairment of property, plant and equipment and right-of-use asset 243,468  
Total operating expenses 34,262,996 32,863,937
Loss from operations (36,669,996) (32,863,937)
Other income (125,536) (88,763)
Finance expense 206,454  
Loss on settlement of financial liability 24,810  
Loss on change in fair value of derivative liability 3,568,305  
Loss (gain) on changes in fair value of other investments 11,669,157 (10,064,550)
Net loss (52,013,186) (22,710,624)
Items that may be subsequently reclassified to income:    
Exchange loss on translation of foreign operations (112,690)  
Comprehensive loss $ (52,125,876) $ (22,710,624)
Net loss per share - basic and diluted (in dollars per share) $ (7.37) $ (3.85)
Weighted average number of shares outstanding - basic and diluted 7,056,245 5,905,252